Linaclotide

In plain language

Linaclotide is an oral capsule for irritable bowel syndrome with constipation (IBS-C) and chronic constipation, sold as Linzess. It is a small ring-shaped peptide that stays in the gut and is barely absorbed into the blood.

It mimics a bacterial toxin that causes traveler's diarrhea, redesigned so that instead of causing illness, it gently pulls water into the intestine and quiets pain nerves. The main side effect is diarrhea, and it must be kept away from young children.

For students

Linaclotide is a 14-residue peptide with three disulfide bonds (about 1,527 Da), an analogue of Escherichia coli heat-stable enterotoxin (STa) that activates the guanylate cyclase C (GC-C) receptor on intestinal epithelial cells. GC-C activation raises intracellular cGMP, which opens the cystic fibrosis transmembrane regulator (CFTR) channel, secreting chloride and water into the lumen.

A second, distinct action is analgesic: extracellular cGMP (exported from cells) is proposed to act on intestinal nociceptors, reducing visceral hypersensitivity, an effect demonstrated in animal models and consistent with the abdominal pain improvement seen independent of bowel movement effects. Because it is minimally absorbed (about 1% bioavailability), systemic side effects are rare. Two Phase 3 IBS-C trials (n=1,170 combined, with the pivotal program totaling over 2,000 patients) showed significant improvements in abdominal pain and complete spontaneous bowel movements.

For researchers and instructors

Biochemistry. GC-C is the same receptor targeted by endogenous uroguanylin and guanylin, and by STa; the disulfide-rich scaffold is a template for oral peptide delivery, since extreme rigidity and low absorption permit gut-restricted action.

Pharmacology. 290 mcg (IBS-C) or 145 mcg (chronic idiopathic constipation) once daily on an empty stomach; contraindicated under age 2 due to juvenile rat deaths; principal adverse effect is diarrhea (about 5% versus 1% placebo).

Human evidence. Two replicate Phase 3 IBS-C trials and two chronic idiopathic constipation trials, each meeting primary endpoints; a reanalysis showed benefit in a moderate-to-severe abdominal pain subgroup.

Teaching point. Teaches how a bacterial toxin's mechanism can be therapeutic, and how peptide drugs can be designed to act locally in the gut without systemic exposure.